Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

Video

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.

Ezra Cohen, MD, FRCPSC, FASCO, chief of the Division of Hematology-Oncology, and a medical oncologist at the University of California, San Diego Health, discusses the goals of the phase 2 SPEARHEAD-2 trial (NCT04408898) in head and neck cancer.

The pilot SPEARHEAD-2 trial is currently enrolling patients with recurrent or metastatic head and neck cancer, says Cohen. The goal of the study is to identify the potential use of ADP-A2M4 plus pembrolizumab (Keytruda) as a rescue therapy for patients who are unresponsive to PD-1 inhibitors alone. There currently aren’t effective options for this subgroup of patients, Cohen explains.

However, eligible patients must be checkpoint inhibitor naïve, PD-L1 positive, MAGE-A4 expressors, and human leukocyte antigen-A*02 positive, says Cohen. Because that subpopulation of patients with recurrent head and neck cancer is limited, clinical trial accrual could be challenging, concludes Cohen.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,